Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04060914
Other study ID # ANZHEN HOSPITOL-LY-01
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date August 30, 2019
Est. completion date December 30, 2021

Study information

Verified date August 2019
Source Beijing Anzhen Hospital
Contact Yi Zhang, PhD
Phone 86-010-64456609
Email phd-zhangyi@outlook.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The hypothesis in this study was that ticagrelor switched to 60 mg after 1 month of standard dose, with antiplatelet activity that is not inferior to the standard dose and better than 75 mg clopidogrel for patients with ACS after PCI.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 225
Est. completion date December 30, 2021
Est. primary completion date December 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Agree to sign the Informed Consent;

- Male or female, = 18 years of age, and = 70 years of age

- Patient presents with acute coronary syndrome (ACS)

- Planned to undergo PCI

- Planned to DAPT for 1 year after PCI

Exclusion Criteria:

- Treatment with other investigational agents (including placebo) or devices within 30 days prior to randomization or planned use of investigational agents or devices prior to the Day 30 visit.

- Patients cannot use ticagrelor or clopidogrel due to contraindications or other reasons.

- Patients with active pathological hemorrhage or a history of intracranial hemorrhage

- Patient unable to receive 12 months of dual anti-platelet therapy

- Patient developing procedure-related complications such as stent thrombosis, coronary dissection, coronary perforation, cardiac tamponade or no-reflow during PCI

- Patient or physician refusal to enroll in the study

- History of intracranial hemorrhage

- Patient has a history of bleeding diathesis or coagulopathy

- Patient has an active pathological bleeding, such as active gastrointestinal (GI) bleeding

- Patient is pregnant, breastfeeding, or planning to become pregnant within 12 months

- Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor)

- Patient with cardiogenic shock or mechanical circulatory assist devices placed

- Patient with active liver diseases

- Patient with severe renal insufficiency (eGFR <30ml/min/1.73m2 based on simplified MDRD equation or CrCl <30ml/min based on Cockcroft-Gault equation)

- Patient has a malignancy or a life expectancy of less than one year

- Platelet count <100 000/µL, or hematocrit <32% or >52%, or white blood cell count <3000/µL

- Any other condition deemed by the investigator to place the patient at excessive risk of bleeding with ticagrelor

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ticagrelor 90mg
Ticagrelor 90 mg plus aspirin for 12 months
Ticagrelor 90mg/60mg
1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months
Clopidogrel 75mg
Clopidogrel 75mg plus aspirin for 12 months

Locations

Country Name City State
China Beijing Anzhen Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Anzhen Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Platelet reactivity index (PRI) Platelet reactivity of ticagrelor or clopidogrel MD will be measured as PRI% using whole blood vasodilator-stimulated phosphoprotein (VASP) at 90 days after PCI. 90 days (±14)
Secondary Occurrence of main adverse cardiovascular and cerebrovascular events (MACCE) MACCE includes all-cause death, non-fatal stroke, non-fatal myocardial infarction (MI), and ischemic-driven revascularization. 1 year
Secondary The platelet aggregation ratio Platelet aggregation of ticagrelor or clopidogrel MD will be measured using the Light Transmittance Aggregometry method at day 90 after PCI. 90 days (±14)
Secondary Plasma adenosine concentration Plasma adenosine concentration in the three treatment groups will be measured using the HPLC-MS at day 90 after PCI. 90 days (±14)
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A